Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
---|---|---|---|---|---|
CD4-H82E3 | Human | Biotinylated Human CD34 Protein, His,Avitag™ (MALS verified) |
|
||
CD4-H52H9 | Human | Human CD34 Protein, His Tag |
|
The purity of Biotinylated Human CD34 Protein, His,Avitag (Cat. No. CD4-H82E3) is more than 90% and the molecular weight of this protein is around 55-75 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Anti-CD34 mab-sirolimus (OrbusNeich) | Approved | Orbusneich | Coronary Restenosis | Orbusneich | 2013-01-01 | Coronary Artery Disease; Coronary Restenosis | Details | |||
Anti-CD34 mab-sirolimus (OrbusNeich) | Approved | Orbusneich | Coronary Restenosis | Orbusneich | 2013-01-01 | Coronary Artery Disease; Coronary Restenosis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CLBS-12 | CLBS-12 | Phase 2 Clinical | Caladrius Biosciences Inc | Atherosclerosis; Thromboangiitis Obliterans; Ischemia | Details |
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA) | Phase 2 Clinical | Ucla Biomedical Library | Adenosine deaminase deficiency | Details | |
CD34+ bone marrow stem cells (University of California) | Phase 2 Clinical | The University Of California Davis | Retinitis Pigmentosa; Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion | Details | |
GSK-2696277 | GSK-2696277; OTL-300 | Phase 2 Clinical | Glaxosmithkline Plc, Ospedale San Raffaele, Fondazione Telethon | beta-Thalassemia | Details |
Autologous peripheral blood stem cell therapy (CellProthera) | Phase 2 Clinical | Cellprothera | Myocardial Infarction | Details | |
CD34 stem cell therapy (LA Childrens Hospital) | Phase 2 Clinical | Children'S Hospital Of Los Angeles | HIV Infections; Heart Failure | Details | |
Stem cell therapeutics (ExCellThera) | ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390 | Phase 2 Clinical | Excellthera Inc | Hematologic Neoplasms; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
Lentiviral vector transduced CD34+ cells Therapy | Phase 2 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Granulomatous Disease, Chronic | Details | |
Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System) | HSC-100 | Phase 1 Clinical | Icahn School Of Medicine At Mount Sinai, Tatcitus Therapeutics | Hematologic Neoplasms; Leukemia; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
shRNA-Modified CD34 Cell Therapy | KL-AI20 | Phase 1 Clinical | Kanglin Biotech (Hangzhou) Co Ltd | HIV Infections | Details |
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis) | Phase 1 Clinical | University Health Network | Fabry Disease | Details | |
Autologous CD34+ Cells Therapy(Genmedicn) | GMCN-508A | Phase 1 Clinical | Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd, First Affiliated Hospital Of Guangxi Medical University | alpha-Thalassemia | Details |
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center) | Phase 1 Clinical | German Cancer Research Center (Dkfz) | Leukemia, Myeloid, Acute | Details | |
CLBS-12 | CLBS-12 | Phase 2 Clinical | Caladrius Biosciences Inc | Atherosclerosis; Thromboangiitis Obliterans; Ischemia | Details |
Retroviral ADA-transduced CD34+ cells (NHGRI/UCLA) | Phase 2 Clinical | Ucla Biomedical Library | Adenosine deaminase deficiency | Details | |
CD34+ bone marrow stem cells (University of California) | Phase 2 Clinical | The University Of California Davis | Retinitis Pigmentosa; Diabetic Retinopathy; Macular Degeneration; Retinal Vein Occlusion | Details | |
GSK-2696277 | GSK-2696277; OTL-300 | Phase 2 Clinical | Glaxosmithkline Plc, Ospedale San Raffaele, Fondazione Telethon | beta-Thalassemia | Details |
Autologous peripheral blood stem cell therapy (CellProthera) | Phase 2 Clinical | Cellprothera | Myocardial Infarction | Details | |
CD34 stem cell therapy (LA Childrens Hospital) | Phase 2 Clinical | Children'S Hospital Of Los Angeles | HIV Infections; Heart Failure | Details | |
Stem cell therapeutics (ExCellThera) | ECT-002; ECT-003; ECT-005; UM171 + UM092; UM171 + UM390 | Phase 2 Clinical | Excellthera Inc | Hematologic Neoplasms; Multiple Myeloma; Leukemia, Myeloid, Acute | Details |
Lentiviral vector transduced CD34+ cells Therapy | Phase 2 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Granulomatous Disease, Chronic | Details | |
Cord blood stem cells(Tatcitus Therapeutics/Mount Sinai Health System) | HSC-100 | Phase 1 Clinical | Icahn School Of Medicine At Mount Sinai, Tatcitus Therapeutics | Hematologic Neoplasms; Leukemia; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
shRNA-Modified CD34 Cell Therapy | KL-AI20 | Phase 1 Clinical | Kanglin Biotech (Hangzhou) Co Ltd | HIV Infections | Details |
Alpha-galactosidase A stem cell therapy (University Health Network/Ozmosis) | Phase 1 Clinical | University Health Network | Fabry Disease | Details | |
Autologous CD34+ Cells Therapy(Genmedicn) | GMCN-508A | Phase 1 Clinical | Zhongji Zhiyao (Nanjing) Biotechnology Co Ltd, First Affiliated Hospital Of Guangxi Medical University | alpha-Thalassemia | Details |
Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion(German Cancer Research Center) | Phase 1 Clinical | German Cancer Research Center (Dkfz) | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.